What Causes Low Platelet Count?

Thrombocytopenia—the medical term for a low platelet count—is defined as a platelet concentration below 150 × 10⁹/L in peripheral blood. Platelets, or thrombocytes, are small, anucleate cell fragments essential for hemostasis and wound healing. When their numbers fall significantly—particularly below 50 × 10⁹/L—patients may experience increased bruising, petechiae, mucosal bleeding (e.g., epistaxis or gingival oozing), or, in severe cases, spontaneous internal hemorrhage.

The underlying causes of thrombocytopenia are broadly categorized into three pathophysiologic mechanisms: decreased production, increased destruction or consumption, and sequestration. Bone marrow disorders—including aplastic anemia, myelodysplastic syndromes, leukemia, lymphoma, and metastatic solid tumors—can impair megakaryocyte maturation and platelet release. Chemotherapy, radiation therapy, and certain medications (e.g., thiazide diuretics, valproic acid, linezolid) also suppress platelet production.

Immune-mediated destruction is another major cause, most notably immune thrombocytopenia (ITP), where autoantibodies target platelet glycoproteins, leading to premature clearance by splenic macrophages. Drug-induced immune thrombocytopenia (e.g., heparin-induced thrombocytopenia or HIT) and post-transfusion purpura represent other immune-related etiologies. Non-immune consumption occurs in conditions such as disseminated intravascular coagulation (DIC), thrombotic microangiopathies (e.g., TTP and HUS), and severe sepsis—where platelets are consumed in widespread microvascular thrombosis.

Splenic sequestration—often secondary to portal hypertension in chronic liver disease or massive splenomegaly from hematologic malignancies or infections like malaria—can transiently lower circulating platelet counts without affecting overall bone marrow output. Additionally, pseudothrombocytopenia, an in vitro artifact caused by EDTA-dependent platelet clumping, must be ruled out before initiating clinical evaluation.

Diagnosis requires a comprehensive assessment: complete blood count with peripheral blood smear review, reticulated platelet count, bone marrow examination when indicated, and targeted serologic or molecular testing (e.g., anti-PF4 antibodies in suspected HIT, ADAMTS13 activity in suspected TTP). Management is etiology-specific—ranging from observation in mild, asymptomatic cases to corticosteroids, intravenous immunoglobulin, thrombopoietin receptor agonists, or splenectomy in ITP; urgent plasma exchange in TTP; or discontinuation of offending agents in drug-induced cases.